Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?

Executive Summary

AbbVie's Humira settlements suggest issues that FTC will be scrutinizing, such as biosimilar entry date, royalty payments, and acceleration clauses.

Advertisement

Related Content

AbbVie's Fourth Humira Patent Settlement Allows Sandoz Biosimilar US Entry Eight Months After Amgen
Sandoz And AbbVie Biosimilar Humira Settlement: What Does It Mean?
Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics
Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention
Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel